RASopathies & RAS-MAPK Signaling

The RAS-MAPK pathway anchors one of the most clinically central signaling families in genetics because germline activating mutations along its length produce a phenotypically overlapping family of conditions called the RASopathies. Together these are the most common single-gene cause of congenital heart disease (Noonan syndrome alone affects ~1/1,000–2,500 births). Recognizing that NF1, Noonan, Costello, CFC, and LEOPARD/Legius are all variations on a single mechanistic theme (germline activation of RAS-MAPK signaling, but tuned-down enough to be compatible with viable development) is one of the unifying concepts in dysmorphology.

The same pathway is the most commonly somatically-activated pathway in cancer (KRAS, BRAF, HRAS, NRAS mutations). The germline RASopathies are essentially "constitutive RAS-MAPK signaling, but mild enough to survive," which is why patients have an increased cancer risk.

Growth factor → RTK → GRB2 / SOS → RAS-GTP → RAF → MEK → ERK → transcription
                                       ↑
                             RAS-GAPs turn it OFF:
                             NF1 (neurofibromin), SPRED1

Key principles:

• RAS (HRAS, KRAS, NRAS) is a small GTPase. Active when bound to GTP, inactive when bound to GDP. It's a binary on/off switch.
• RAS-GAPs (GTPase-activating proteins) accelerate GTP hydrolysis, switching RAS off. NF1's neurofibromin is a RAS-GAP. SPRED1 (Legius syndrome) regulates neurofibromin.
• RAS-GEFs (guanine-exchange factors) like SOS load GTP onto RAS, switching it on. SOS1 mutations cause Noonan.
• PTPN11/SHP2 is a phosphatase upstream of RAS that amplifies RTK signaling. ~50% of Noonan cases have PTPN11 mutations.
• The downstream cascade (RAF → MEK → ERK) is also a mutation hotspot. BRAF activates → CFC and Costello-like phenotypes.

A useful frame: anything that pushes the pathway "more on" (gain-of-function in RAS, RAF, MEK, SHP2, SOS, or loss of RAS-GAPs like NF1, SPRED1) produces a RASopathy.

Cardiac signature: pulmonic valve stenosis is the canonical RASopathy CHD (Noonan, CFC, LEOPARD). HCM is also common. Compare with Williams syndrome (ELN) which gives supravalvular aortic stenosis; pathway and gene are completely different even though both are valvular issues in syndromic kids.

The clinical features cluster because RAS-MAPK signaling is required for the same developmental processes across syndromes:

• Cardiac valve and septal development → pulmonic stenosis, HCM, AV canal
• Lymphatic development → lymphedema, cystic hygroma in fetal life (causing the broad neck appearance)
• Bone growth and craniofacial morphogenesis → short stature, facial coarseness, pectus
• Skin/hair (ectodermal) → café-au-lait, sparse curly hair (CFC), papillomata (Costello)
• CNS development & learning → variable ID, learning disability
• Hematopoiesis → juvenile myelomonocytic leukemia (JMML) susceptibility in Noonan with PTPN11 mutations

RAS-MAPK is the most-mutated pathway in human cancer. Germline RASopathy patients are at increased cancer risk because their cells already start with elevated baseline pathway activity:

• Costello (HRAS): highest cancer risk. Rhabdomyosarcoma (1st 5 years of life), neuroblastoma, transitional cell carcinoma. Surveillance protocol with abdominal ultrasound + urinalysis.
• Noonan with PTPN11: JMML, ALL, neuroblastoma. Can have transient myeloproliferative-like disorder in infancy.
• NF1: optic pathway gliomas (10–20% in childhood, often indolent), MPNST (malignant peripheral nerve sheath tumor) in adulthood, breast cancer in women, pheochromocytoma, GIST.
• CFC, LEOPARD: modestly increased risk; less clear surveillance protocol.

Germline mutations are tuned by selection: too much pathway activation is embryonic-lethal, which is why germline RAS mutations are missense (not truncating) and target specific residues.

• Phenotypic recognition first: characteristic facies (especially Noonan's broad-tip/upturned-pointed nose, downslanting palpebral fissures, low-set rotated ears) is often more sensitive than genetic testing.
• Multigene panel rather than single-gene testing: a Noonan/RASopathy panel covers ~80–95% of clinical cases.
• Echocardiogram at diagnosis (pulmonic stenosis, HCM) and follow-up.
• Cancer surveillance depends on specific gene (most rigorous for Costello and NF1).

• NF1 is autosomal dominant with very high penetrance but variable expressivity. ~50% of cases are de novo (NF1 has the highest spontaneous mutation rate of any human gene, likely related to the gene's enormous size, ~280 kb).
• Noonan is autosomal dominant; many cases are de novo, with paternal age effect for some genes.
• Costello is essentially always de novo HRAS mutation with strong paternal age effect.
• Recurrence after a de novo case is generally low (<1%) but parental mosaicism can elevate it; gonadal mosaicism makes "0% recurrence" counseling unsafe.